Table 1.

Summary of primary neuroendocrine carcinoma of the breast cases published in the indexed literature ( n =83)^a

						Neuroendocrine IHC					Hormonal receptors			Treatment
Author (year) [Ref]	Age (years)/Sex	Site	Size (cm)b	TNM	IS	GML	NSE	CgA/B	Syn	NSG	ER	PR	HER2/Neu	Neoadjuvant	Surgical	Adjuvant	Follow-up (months)	Outcome
Wade (1983) [18]	52/F	R	10.0	T4N1M0	-	-				+	NS	NS	NS	NS	Mast/ALND	Ch	9	DOD
Jundt (1984) [16]	52/M	R	NS	TxN1M0	NS	-	+			+	NS	NS	NS	NS	NS	Ch/RT	14	DOD
Papotti (1992) [19]	64/F	R	2.0	T1N0M0	+	-	-	-	-		-	NS	NS	NS	Mast/ALND	NS	44	NED
	41/F	L	3.5	T2NxM0	+	-	+	-	-	+	-	NS	NS	NS	Mast/ALND	RT	15	DOD
	41/F	L	3.0	T2NxM0	+	+	+	+	+	+	-	NS	NS	NS	Mast/ALND	Ch	14	LR/DOD
	69/F	L	5.0	T3NxM0	+	+	+	-	+		+	NS	NS	NS	Mast/ALND	HT	9	DOD
Papotti (1993) [17]	83/M	R	1.5	T1N0M0	+	+	+	+			-	NS	NS	NS	Mast	NS	84	DOD
Francois (1995) [20]	68/F	R	4.5	T2N0M0	NS			+			-	-	NS	-	Mast/ALND	RT	21	D-NOS
Chua (1997) [21]	45/F	L	NS	T2N0Mx	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	BCS	NS	NS	NS
Fukunaga (1998) [22]	56/F	R	10.0	T3NxM0	+			+	+		-	-	NS	-	Mast/ALND	-	48	NED
Samli (2000) [23]	60/F	L	8.0	T4N1M0	NS			+	+		NS	NS	NS	Ch	Mast/ALND	Ch/RT	6	LR
Shin (2000) [24]	43/F	R	1.3	T1NxM0	NS		+				NS	NS	-	-	BCS	RT	30	NED
	44/F	L	2.0	T1NxM0	NS		+				NS	NS	-	-	BCS/ALND	Ch/RT	27	NED
	46/F	R	3.4	T2NxM0	NS		+				NS	NS	-	-	Mast/ALND	Ch	11	AWM
	50/F	R	2.2	T2NxM0	+		+				NS	NS	-	-	BCS/ALND	Ch/HT	35	NED
	51/F	R	1.5	T1NxM0	NS		+				NS	NS	-	-	BCS/ALND	RT	25	NED
	57/F	L	2.5	T2NxM0	NS		+				NS	NS	-	-	Mast/ALND	Ch	10	NED
	62/F	L	5.0	T3NxM0	+		+				NS	NS	-	Ch	Mast/ALND	Ch/HT	32	AWM
	64/F	L	1.8	T1NxM0	NS		+				NS	NS	-	-	BCS/ALND	Ch	10	NED
	70/F	L	4.0	T2NxM0	+		+				NS	NS	-	-	BCS/ALND	Ch/RT	3	NED
Yamasaki (2000) [25]	41/F	R	4.5	T2N0M0	+			+			-	NS	NS	-	BCS/Mast/ALND	Ch	16	NED
Salmo (2001) [26]	46/F	R	4.0	T2N0M0	+	+	NS	NS	NS	NS	-	+	NS	-	BCS	Ch/RT	9	NED
Zekioglu (2003) [27]	79/F	R	1.5	T1N0M0	+		+	+	-		+	+	NS	NS	Mast/ALND	NS	24	NED
	76/F	L	2.2	T2N0M0	+		+	+	+		+	+	NS	NS	BCS	NS	18	NED
	65/F	R	3.5	T2N0M0	+		+	-	+		+	+	NS	NS	Mast/ALND	NS	16	NED
	68/F	R	7.0	T3N1M0	+		+	+	+		-	-	NS	NS	Mast/ALND	NS	22	NED
	69/F	R	1.0	T1N0M0	+		+	+	+		+	+	NS	NS	Mast/ALND	NS	12	NED
	72/F	R	1.5	T1N0M0	+		+	-	+		+	+	NS	NS	BCS	NS	13	NED
	60/F	R	1.0	T1N0M0	+		+	+	+		+	+	NS	NS	BCS	NS	10	NED
	43/F	L	0.8	T1N0M0	+		+	-	+		+	+	NS	NS	BCS	NS	48	NED
	60/F	L	2.5	T2N0M0	+		+	-	+		+	+	NS	NS	Mast/ALND	NS	54	NED
	43/F	L	5.0	T2N0M0	+		+	-	+		+	+	NS	NS	BCS	NS	NS	NED
	72/F	L	2.7	T2N0M0	+		+	-	+		+	+	NS	NS	BCS	NS	NS	NED
	72/F	L	2.7	T2N0M0	+		+	-	+		+	+	NS	NS	Mast/ALND	NS	NS	NED
Bergman (2004) [28]	61/F	L	2.5	T2NxM0	+		+	-	-		-	-	-	-	Mast/ALND	NS	NS	NS
Bigotti (2004) [29]	56/F	L	18.0	T3N1M0	+		+	-	+		-	-	-	Ch	Mast	Ch	14	D-N0S
Jochems (2004) [30]	71/F	NS	3.0	T2NxM0	NS		+	+	+		+	+	-	-	Mast/ALND	HT	12	NED
Sridhar (2004) [31]	58/F	R	2.0	T1NxM0	NS			-			-	-	NS	-	BCS/ALND	Ch/RT	18	NED
Yamamoto (2004) [32]	53/F	NS	6.5	T3N2M0	NS		+				NS	NS	NS	NS	NS	NS	34	NED
	75/F	NS	2.0	T2N1M0	NS		+				NS	NS	NS	NS	NS	NS	43	NED
Berruti (2004) [33]	59/F	NS	NS	T2N0M0	+		+	+	+		+	-	NS	-	Mast	HT	NS	AWM
Adegbola (2005) [34]	46/F	R	1.0	T1N0M0	NS			+	+		-	-	-	-	BCS	Ch/RT	48	NED
	60/F	R	1.7	T1NxM0	+			+	+		-	-	-	-	BCS	Ch/RT	20	D-NOS
	61/F	L	1.7	T1NxM0	NS			+			-	-	-	-	BCS	Ch/RT	6	AWM
Valdes (2006) [35]	41/F	R/MF	1.5	T1NxM0	+				+		-	-	NS	-	Mast/SLNB/Re	Ch	NS	NS
Fujimoto (2007) [36]	40/F	L/MF	2.0	T1NxM0	+			+	+		+	+	+	-	Mast/SLNB	HT	36	NED
Kim (2008) [37]	27/F	L	3.2	T2NxM0	NS		+	+	+		NS	NS	NS	-	BCS/ALND	Ch/RT	18	NED
Kinoshita (2008) [9]	31/F	L	6.0	T3NxM0	+		+	+			-	-	-	Ch	Mast/ALND	Ch	9	D-NOS
Stita (2009) [38]	64/F	L	3.0	T2NxM0	+		+	+			+	+	NS	-	Mast/ALND	Ch	8	NED
Yamaguchi (2009) [39]	51/F	R	3.0	T2NxM0	NS			+	+		-	-	-	-	Mast/ALND	Ch	12	AWM
Christie (2010) [40]	61/F	L	3.0	T2NxM0	+			+	+		-	-	-	-	BCS/ALND	Ch	3	D-NOS
Latif (2010) [41]	53 /F	R	6.0	T3N0M0	NS			+	+		-	-	-	Ch	BCS/SLNB	RT	NS	NS
Honami (2011) [42]	54/F	B	L: 1.0	T1N0M0	L: +			+	+		+	+	-	-	BCS	RT	18	NED
			R: 1.5		R: +
Kawanishi (2011) [43]	67/F	R	0.8	T1NxM0	+			+	+		+	+	-	-	BCS/ SLNB	HT	12	NED
Nozoe (2011) [44]	57/F	R	3.0	T2NxM0	NS		+		+		+	+	-	-	Mast/ALND	Ch	NS	NS
Zhang (2011) [45]	29/F	B	L: 8.5	T1N2M0	L: +		+	+	+		+	+	-	-	BCS	Ch	NS	NS
			R: 2.0		R: +
Su (2012) [46]	75/F	L	4.0	T2N0M0	NS			+	+		+	+	-	-	Mast/ALND	HT	20	NED
Miura (2012) [47]	72/F	R/MC	1.5	T1N0M0	Both +			+	+		+	+	-	NS	Mast/SLNB	NS	NS	NS
Kawasaki (2012) [48]	41/F	L	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	101	NED
	45/F	R	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	80	NED
	41/F	L	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	90	NED
	74/F	R	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	91	NED
	28/F	R	0.0	TisN0M0	+			+	+		+	+	NS	NS	Mast	NS	77	NED
	30/F	L	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	86	NED
	58/F	R	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	96	NED
	36/F	L	0.0	TisN0M0	+			+	+		+	+	NS	NS	BCS	NS	64	NED
	38/F	R	0.0	TisN0M0	+			+	+		+	+	NS	NS	Mast	NS	69	NED
	60/F	L	0.1	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	84	NED
	42/F	L	0.1	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	73	NED
	43/F	R	0.1	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	80	NED
	35/F	R	0.1	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	100	NED
	70/F	L	0.1	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	93	NED
	72/F	R	0.1	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	66	NED
	62/F	L	0.1	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	88	NED
	38/F	R	0.2	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	85	NED
	73/F	R	0.3	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	71	NED
	43/F	L	0.4	T1N1M0	+			+	+		+	+	NS	NS	BCS	NS	86	NED
	42/F	L	0.5	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	96	NED
	39/F	R	0.5	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	74	NED
	33/F	R	0.7	T1N0M0	+			+	+		+	+	NS	NS	Mast	NS	92	NED
	36/F	L	1.5	T1N0M0	+			+	+		+	+	NS	NS	BCS	NS	99	NED
	68/F	R	2.5	T2N0M0	+			+	+		+	+	NS	NS	Mast	NS	68	NED
(2012) [Present case]	51/F	R	2.0	T4aN0M0	+			+	+		+	-	-	Ch/RT	Mast/ALND	Ch/HT	13	AWM

^aStudies included in this table are those available in PubMed as of May 31, 2012. Papers that were excluded from this summary are those in which information was not provided explicitly in the description of the case report or because the results were grouped into cohorts [12,49,57].

^bObtained either from clinical history or the final pathology report; for multifocal or multicentric disease the largest tumor was registered.

ALND, axillary lymph node dissection; AWM, alive with metastatic disease; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but cause not otherwise specified; DOD, dead of other disease; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast in situ component; LR, local recurrence; M, male; Mast, mastectomy; MC, multicentric; MF, multifocal; NED; no evidence of disease; NS, information not specified; NSE, neuron-specific enolase; NSG, neurosecretory granules; PR, progesterone receptors; R, right; Re, reconstruction; RT, radiation therapy; SLNB, sentinel lymph node biopsy; Syn, synaptophysin.